What is the clinical effect of domestically produced cemiplimab?

Cemiplimab (Cemiplimab) is an immune checkpoint inhibitor targeting the PD-1 pathway. Currently, there are no domestic generic drugs on the market in China, and patients mainly rely on the American or European versions of the original drugs. According to overseas clinical practice and drug application experience, cimepilimab has shown promising clinical effects in a variety of malignant tumors, especially in cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC), non-small cell lung cancer (NSCLC) and other populations. The principle is to reactivate the killing function of T cells by blocking the inhibitory signals between tumor cells and the immune system, so that the body's immune system can recognize and attack cancer cells.

Compared with traditional chemotherapy drugs, cimepilimab does not directly kill cancer cells, but achieves therapeutic effects by regulating the immune system, which makes its effects more long-term and stable. Overseas real-world studies have shown that some patients can maintain a long-term remission state after receiving cimepilimab treatment, and even achieve the possibility of long-term survival. This"sustained response" is an important advantage that distinguishes immunotherapy drugs from traditional therapies.

However, the efficacy of cimepilimab is not effective for all patients. Different patients have different treatment responses due to differences in tumor type, genetic characteristics and immune environment. Some patients may not show significant improvement in the early stages of treatment, but gradually show positive clinical responses as the course of treatment progresses. At the same time, immune-related adverse reactions also need to be paid attention to, such as rash, thyroid dysfunction or lung inflammation. These side effects are usually related to immune activation and require close monitoring and management by professional doctors.

In general, domestically produced cimepilimab has not yet been launched on the market, but the imported original drug has been proven to have good efficacy and safety overseas. Cimepilimab represents a new treatment option for cancer patients, offering hope to those who lack effective options.

Reference materials:https://www.libtayohcp.com/